Pacira BioSciences, Inc. (PCRX) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $26.21 (-2.52%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 30, 2025 | Les Sulewski | Truist Financial | $25.00 | -4.6% |
| Nov 7, 2024 | David Amsellem | Piper Sandler | $12.00 | -54.2% |
| Sep 24, 2024 | Glen Santangelo | Jefferies | $18.00 | -31.3% |
| Aug 13, 2024 | Les Sulewski | Truist Financial | $8.00 | -69.5% |
| Jul 2, 2024 | Oren Livnat | H.C. Wainwright | $57.00 | +117.5% |
| Jun 13, 2024 | Glen Santangelo | Jefferies | $36.00 | +37.4% |
| May 21, 2024 | David Amsellem | Piper Sandler | $42.00 | +60.2% |
Top Analysts Covering PCRX
PCRX vs Sector & Market
| Metric | PCRX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.50 | 2.25 | 2.42 |
| Analyst Count | 4 | 8 | 19 |
| Target Upside | +23.4% | +16366.1% | +18.0% |
| P/E Ratio | 216.08 | 2.81 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $190M | $191M | $193M | 2 |
| 2026-12-31 | $205M | $206M | $209M | 3 |
| 2027-03-31 | $191M | $192M | $195M | 3 |
| 2027-06-30 | $202M | $204M | $206M | 2 |
| 2027-09-30 | $210M | $211M | $214M | 2 |
| 2027-12-31 | $220M | $222M | $225M | 3 |
| 2028-12-31 | $960M | $960M | $960M | 4 |
| 2029-12-31 | $912M | $923M | $940M | 3 |
| 2030-12-31 | $922M | $933M | $950M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $0.68 | $0.69 | $0.70 | 1 |
| 2026-12-31 | $0.67 | $0.68 | $0.69 | 2 |
| 2027-03-31 | $0.65 | $0.66 | $0.67 | 2 |
| 2027-06-30 | $0.79 | $0.80 | $0.81 | 1 |
| 2027-09-30 | $0.84 | $0.85 | $0.87 | 1 |
| 2027-12-31 | $0.94 | $0.96 | $0.97 | 2 |
| 2028-12-31 | $4.70 | $4.77 | $4.88 | 3 |
| 2029-12-31 | $4.53 | $4.60 | $4.71 | 2 |
| 2030-12-31 | $4.87 | $4.95 | $5.07 | 2 |
Frequently Asked Questions
What is the analyst consensus for PCRX?
The consensus among 4 analysts covering Pacira BioSciences, Inc. (PCRX) is Buy with an average price target of $32.00.
What is the highest price target for PCRX?
The highest price target for PCRX is $57.00, set by Oren Livnat at H.C. Wainwright on 2024-07-02.
What is the lowest price target for PCRX?
The lowest price target for PCRX is $8.00, set by Les Sulewski at Truist Financial on 2024-08-13.
How many analysts cover PCRX?
4 analysts have issued ratings for Pacira BioSciences, Inc. in the past 12 months.
Is PCRX a buy or sell right now?
Based on 4 analyst ratings, PCRX has a consensus rating of Buy (2.50/5) with a +23.4% upside to the consensus target of $32.00.
What are the earnings estimates for PCRX?
Analysts estimate PCRX will report EPS of $0.69 for the period ending 2026-09-30, with revenue estimated at $191M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.